NO20045331L - Piperazinylacylpiperidinderivater, deres fremstilling og terapeutisk anvendelse derav - Google Patents
Piperazinylacylpiperidinderivater, deres fremstilling og terapeutisk anvendelse deravInfo
- Publication number
- NO20045331L NO20045331L NO20045331A NO20045331A NO20045331L NO 20045331 L NO20045331 L NO 20045331L NO 20045331 A NO20045331 A NO 20045331A NO 20045331 A NO20045331 A NO 20045331A NO 20045331 L NO20045331 L NO 20045331L
- Authority
- NO
- Norway
- Prior art keywords
- group
- radical
- halogen atom
- atom
- therapeutic use
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 3
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- -1 trifluoromethoxy radical Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Den foreliggende oppfinnelse vedrører 1-substituerte piperazinylacylpiperidinderivater med generell formel (I) hvori: n er 1 eller 2; p er 1 eller 2; Ri representerer et halogenatom, et trifluormetylradikal, et C- Calkylradikal, et C-C- alkoksyradikal, et trifluormetoksyradikal; Rrepresenterer et hydrogenatom eller et halogenatom; Rrepresenterer et hydrogenatom, en -ORgruppe, en -CHORgruppe, en -NRRy gruppe, en -NRCORgruppe, en -NRCONRRgruppe, en -CHNRRgruppe, en -CHNRCONRRgruppe, en C-Calkoksykarbonylgruppe, en -CONRRgruppe; eller Rdanner en dobbeltbinding mellom karbonatomet hvortil det er bundet og det nærliggende karbonatom i piperidinringen; Rrepresenterer en aromatisk gruppe valgt blant (II), hvor de aromatiske gruppene er usubstituerte, monosubstituerte eller disubstituerte med en substituent som uavhengig er valgt blant et halogenatom, et C-C-alkylradikal, et C-Calkoksyradikal, et trifluormetylradikal.oppfinnelsen vedrører også en fremgangsmåte for å fremstille de nevnte forbindelser og deres terapeutiske anvendelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207001 | 2002-06-07 | ||
| PCT/FR2003/001685 WO2003104225A1 (fr) | 2002-06-07 | 2003-06-05 | Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20045331L true NO20045331L (no) | 2005-03-07 |
| NO329669B1 NO329669B1 (no) | 2010-11-29 |
Family
ID=29724874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045331A NO329669B1 (no) | 2002-06-07 | 2004-12-06 | Piperazinylacylpiperidinderivater, deres fremstilling og terapeutiske anvendelse |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7294628B2 (no) |
| EP (2) | EP1513836B1 (no) |
| JP (2) | JP4441401B2 (no) |
| KR (1) | KR100970812B1 (no) |
| CN (1) | CN100448875C (no) |
| AR (2) | AR040247A1 (no) |
| AT (2) | ATE325122T1 (no) |
| AU (2) | AU2003255645A1 (no) |
| BR (1) | BR0311828A (no) |
| CA (1) | CA2487840C (no) |
| CY (2) | CY1107330T1 (no) |
| DE (2) | DE60307632T2 (no) |
| DK (2) | DK1513835T3 (no) |
| EA (1) | EA007501B1 (no) |
| ES (2) | ES2264001T3 (no) |
| HR (1) | HRP20041157B1 (no) |
| IS (1) | IS2302B (no) |
| MA (1) | MA27233A1 (no) |
| ME (1) | MEP11508A (no) |
| MX (1) | MXPA04012341A (no) |
| NO (1) | NO329669B1 (no) |
| NZ (1) | NZ537044A (no) |
| PL (1) | PL208711B1 (no) |
| PT (2) | PT1513836E (no) |
| RS (2) | RS52588B (no) |
| TW (2) | TWI319400B (no) |
| UA (1) | UA77526C2 (no) |
| WO (2) | WO2003104225A1 (no) |
| ZA (1) | ZA200409823B (no) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| US7723362B2 (en) * | 2004-01-08 | 2010-05-25 | Syngenta Crop Protection, Inc. | Pesticidal heterocyclic dihaloallyl compounds |
| CN1984910A (zh) * | 2004-07-16 | 2007-06-20 | 詹森药业有限公司 | 适用于神经变性疾病治疗的哌啶、哌嗪或者吗啉或它们的7元类似物的二聚化合物 |
| EP2289510A1 (en) * | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| EP1871420A4 (en) | 2005-04-15 | 2010-09-22 | Univ North Carolina | PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS |
| CL2008000725A1 (es) * | 2007-03-15 | 2008-11-14 | Schering Corp | Compuestos derivados de heterociclos aromaticos; composicion farmaceutica; kit farmceuticos; uso de la composicion y de los compuestos como inhibidores de glucano sintasa para el tratamiento o prevencion del crecimiento de patogenos fungicos en planta y para tratar o prevenir infecciones producidas por hongos. |
| JP5466147B2 (ja) * | 2007-05-21 | 2014-04-09 | レビバ ファーマシューティカルズ，インコーポレーテッド | キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法 |
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| FR2932482B1 (fr) * | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| FR2932481B1 (fr) * | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique. |
| CN102740856B (zh) | 2009-11-12 | 2015-02-18 | 特罗菲克斯制药股份有限公司 | 神经营养蛋白模拟化合物及其盐的晶型 |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| FR2953836B1 (fr) * | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| AU2010333338A1 (en) | 2009-12-14 | 2012-08-02 | Merck Patent Gmbh | Sphingosine kinase inhibitors |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| AU2018334290A1 (en) | 2017-09-18 | 2020-04-02 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| IL281438B2 (en) | 2018-09-18 | 2023-12-01 | Goldfinch Bio Inc | Pyridazinones and methods of use thereof |
| MX2021012310A (es) | 2019-04-11 | 2021-11-12 | Goldfinch Bio Inc | Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona. |
| EP3858439A1 (en) * | 2020-02-03 | 2021-08-04 | Esteve Pharmaceuticals, S.A. | Amide derivatives having multimodal activity against pain |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU206109B (en) * | 1987-10-26 | 1992-08-28 | Pfizer | Process for producing heterocyclic carbonylpropyl pyrimidinyl piperazine derivatives and pharmaceutical compositions comprising same |
| FR2747041B1 (fr) * | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| FR2803593B1 (fr) * | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
-
2003
- 2003-05-06 UA UA20041210010A patent/UA77526C2/uk unknown
- 2003-06-05 BR BR0311828-2A patent/BR0311828A/pt not_active IP Right Cessation
- 2003-06-05 US US10/516,808 patent/US7294628B2/en not_active Expired - Lifetime
- 2003-06-05 EP EP03757109A patent/EP1513836B1/fr not_active Expired - Lifetime
- 2003-06-05 RS RS20050014A patent/RS52588B/sr unknown
- 2003-06-05 WO PCT/FR2003/001685 patent/WO2003104225A1/fr not_active Ceased
- 2003-06-05 KR KR1020047019860A patent/KR100970812B1/ko not_active Expired - Fee Related
- 2003-06-05 PT PT03757109T patent/PT1513836E/pt unknown
- 2003-06-05 DK DK03757108T patent/DK1513835T3/da active
- 2003-06-05 ME MEP-115/08A patent/MEP11508A/xx unknown
- 2003-06-05 EA EA200401470A patent/EA007501B1/ru not_active IP Right Cessation
- 2003-06-05 PT PT03757108T patent/PT1513835E/pt unknown
- 2003-06-05 WO PCT/FR2003/001686 patent/WO2003104226A1/fr not_active Ceased
- 2003-06-05 DE DE60307632T patent/DE60307632T2/de not_active Expired - Lifetime
- 2003-06-05 ES ES03757109T patent/ES2264001T3/es not_active Expired - Lifetime
- 2003-06-05 NZ NZ537044A patent/NZ537044A/en not_active IP Right Cessation
- 2003-06-05 RS YUP-2005/0014A patent/RS20050014A/sr unknown
- 2003-06-05 MX MXPA04012341A patent/MXPA04012341A/es active IP Right Grant
- 2003-06-05 PL PL374729A patent/PL208711B1/pl not_active IP Right Cessation
- 2003-06-05 JP JP2004511296A patent/JP4441401B2/ja not_active Expired - Fee Related
- 2003-06-05 AT AT03757109T patent/ATE325122T1/de active
- 2003-06-05 US US10/516,704 patent/US7468368B2/en not_active Expired - Lifetime
- 2003-06-05 ES ES03757108T patent/ES2271637T3/es not_active Expired - Lifetime
- 2003-06-05 HR HR20041157 patent/HRP20041157B1/xx not_active IP Right Cessation
- 2003-06-05 DE DE60305037T patent/DE60305037T2/de not_active Expired - Lifetime
- 2003-06-05 DK DK03757109T patent/DK1513836T3/da active
- 2003-06-05 JP JP2004511295A patent/JP4437075B2/ja not_active Expired - Fee Related
- 2003-06-05 CA CA2487840A patent/CA2487840C/en not_active Expired - Fee Related
- 2003-06-05 EP EP03757108A patent/EP1513835B1/fr not_active Expired - Lifetime
- 2003-06-05 CN CNB038188082A patent/CN100448875C/zh not_active Expired - Fee Related
- 2003-06-05 AU AU2003255645A patent/AU2003255645A1/en not_active Abandoned
- 2003-06-05 AT AT03757108T patent/ATE336491T1/de active
- 2003-06-05 AU AU2003255644A patent/AU2003255644B2/en not_active Ceased
- 2003-06-06 AR ARP030102018A patent/AR040247A1/es active IP Right Grant
- 2003-06-06 AR ARP030102017A patent/AR040246A1/es active IP Right Grant
- 2003-06-06 TW TW092115443A patent/TWI319400B/zh not_active IP Right Cessation
- 2003-06-06 TW TW092115416A patent/TWI283671B/zh not_active IP Right Cessation
-
2004
- 2004-12-02 IS IS7579A patent/IS2302B/is unknown
- 2004-12-03 ZA ZA200409823A patent/ZA200409823B/en unknown
- 2004-12-03 MA MA27980A patent/MA27233A1/fr unknown
- 2004-12-06 NO NO20045331A patent/NO329669B1/no not_active IP Right Cessation
-
2006
- 2006-08-03 CY CY20061101094T patent/CY1107330T1/el unknown
- 2006-11-15 CY CY20061101660T patent/CY1105784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200401470A1 (ru) | Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение | |
| DK0958296T3 (da) | Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme | |
| NO20063501L (no) | Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese | |
| DK0794949T3 (da) | Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler | |
| DE60315323D1 (de) | Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden | |
| DK1270584T3 (da) | Glucopyranosyloxybenzylbenzenderivater, medicinske sammensætninger indeholdende samme og intermediater til fremstilling af derivaterne | |
| TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
| LU92113I2 (fr) | Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA) | |
| DK1474406T3 (da) | Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider | |
| NO20074763L (no) | (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi | |
| NO20060219L (no) | Forbindelser | |
| NO20074718L (no) | BCRP/ABCG2 inhibitor | |
| NO20075384L (no) | Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer. | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| NO20071008L (no) | Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater | |
| NO20062617L (no) | Anvendelse av glukosidase inhibitorer for terapi av mucovisidose | |
| TW200510377A (en) | Novel compound having 4-pyridylalkylthio group as substituent | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| NO20001781L (no) | 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse | |
| NO20082226L (no) | 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav | |
| ES2191341T3 (es) | Derivados de la 2-fenoxianilina. | |
| ATE442354T1 (de) | Pyrrolidinderivate als oxytocin antagonisten | |
| NO20062936L (no) | Fremgangsmate for fremstilling av N-alkyl-2(hydroksy-4-benzoyl)-3-benzofuraner og dets mellomprodukter derav | |
| NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |